21.03
price up icon1.35%   0.28
after-market 시간 외 거래: 21.28 0.25 +1.19%
loading
전일 마감가:
$20.75
열려 있는:
$21.11
하루 거래량:
2.93M
Relative Volume:
1.42
시가총액:
$2.11B
수익:
$352.57M
순이익/손실:
$-143.01M
주가수익비율:
-11.62
EPS:
-1.81
순현금흐름:
$-153.40M
1주 성능:
-0.66%
1개월 성능:
+25.48%
6개월 성능:
-14.27%
1년 성능:
-18.93%
1일 변동 폭
Value
$20.85
$22.80
1주일 범위
Value
$19.40
$22.80
52주 변동 폭
Value
$13.53
$35.25

빔 테라퓨틱스 Stock (BEAM) Company Profile

Name
명칭
Beam Therapeutics Inc
Name
전화
857-327-8775
Name
주소
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Name
직원
502
Name
트위터
Name
다음 수익 날짜
2024-11-05
Name
최신 SEC 제출 서류
Name
BEAM's Discussions on Twitter

BEAM을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
BEAM
Beam Therapeutics Inc
21.03 2.13B 352.57M -143.01M -153.40M -1.81
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
458.49 121.30B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
545.53 61.60B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
320.52 41.17B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
566.14 34.35B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.93 27.29B 3.81B -644.79M -669.77M -6.24

빔 테라퓨틱스 Stock (BEAM) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-03-28 업그레이드 BofA Securities Neutral → Buy
2025-03-10 업그레이드 Scotiabank Sector Perform → Sector Outperform
2025-01-29 업그레이드 Cantor Fitzgerald Neutral → Overweight
2024-11-06 업그레이드 Leerink Partners Market Perform → Outperform
2024-10-16 개시 Scotiabank Sector Outperform
2024-07-23 개시 H.C. Wainwright Buy
2024-01-29 업그레이드 JP Morgan Neutral → Overweight
2023-12-15 다운그레이드 BofA Securities Buy → Neutral
2023-12-08 다운그레이드 Jefferies Buy → Hold
2023-10-20 다운그레이드 Cantor Fitzgerald Overweight → Neutral
2023-10-20 다운그레이드 Leerink Partners Outperform → Market Perform
2023-03-21 개시 Bernstein Mkt Perform
2023-02-01 개시 Cantor Fitzgerald Overweight
2022-12-20 업그레이드 BMO Capital Markets Market Perform → Outperform
2022-12-13 개시 Citigroup Buy
2022-06-17 개시 BMO Capital Markets Market Perform
2022-04-28 개시 Credit Suisse Neutral
2022-01-05 개시 Guggenheim Buy
2021-10-19 개시 SVB Leerink Outperform
2021-09-24 재개 Stifel Buy
2021-09-10 개시 BofA Securities Buy
2021-05-11 개시 Redburn Buy
2021-05-04 개시 RBC Capital Mkts Sector Perform
2021-03-01 다운그레이드 Barclays Overweight → Equal Weight
2021-02-16 개시 Wells Fargo Overweight
2021-01-29 다운그레이드 JP Morgan Overweight → Neutral
2021-01-06 개시 Stifel Hold
2020-08-05 개시 William Blair Outperform
2020-03-02 개시 Barclays Overweight
2020-03-02 개시 JP Morgan Overweight
2020-03-02 개시 Jefferies Buy
2020-03-02 개시 Wedbush Outperform
모두보기

빔 테라퓨틱스 주식(BEAM)의 최신 뉴스

pulisher
Jul 21, 2025

Is Beam Therapeutics Inc. a good long term investmentHigh-impact investment strategies - Autocar Professional

Jul 21, 2025
pulisher
Jul 21, 2025

Beam Therapeutics Inc. Stock Analysis and ForecastUnstoppable trading performance - Autocar Professional

Jul 21, 2025
pulisher
Jul 21, 2025

What drives Beam Therapeutics Inc. stock priceRapid-fire capital growth - Autocar Professional

Jul 21, 2025
pulisher
Jul 21, 2025

Sickle Cell Disease Market Set to Grow Substantially Through 2034, DelveInsight Projects | Sanofi, CSL Behring, ITB-Med LLC, Novo Nordisk A/S, Fortrea, Inc., Novartis, Afimmune, Pfizer, ADDMEDICA SASA - The Globe and Mail

Jul 21, 2025
pulisher
Jul 21, 2025

Beam Therapeutics (BEAM) Announces Acquisition of an Early-Stage Life Sciences Company - MSN

Jul 21, 2025
pulisher
Jul 18, 2025

What analysts say about Beam Therapeutics Inc. stockHigh-yield capital appreciation - jammulinksnews.com

Jul 18, 2025
pulisher
Jul 16, 2025

12 Oversold NASDAQ Stocks to Buy Now - Insider Monkey

Jul 16, 2025
pulisher
Jul 14, 2025

(BEAM) Trading Report - news.stocktradersdaily.com

Jul 14, 2025
pulisher
Jul 13, 2025

Beam Therapeutics (BEAM) Surges 5.7%: Is This an Indication of Further Gains? - MSN

Jul 13, 2025
pulisher
Jul 08, 2025

H.C. Wainwright Reiterates a Buy Rating on Beam Therapeutics (BEAM) With an $80 PT - MSN

Jul 08, 2025
pulisher
Jul 06, 2025

Beam Therapeutics: A Base Editing Breakthrough With Catalysts to Ignite Value - AInvest

Jul 06, 2025
pulisher
Jul 04, 2025

Beam Therapeutics’ BEAM-101 Shows Promising Results in Sickle Cell Disease Trial - MSN

Jul 04, 2025
pulisher
Jul 04, 2025

Beam Therapeutics Acquires Early-Stage Life Sciences Firm - The Globe and Mail

Jul 04, 2025
pulisher
Jul 01, 2025

H.C. Wainwright reiterates Buy rating on Beam Therapeutics stock at $80 target - Investing.com

Jul 01, 2025
pulisher
Jun 30, 2025

Beam Therapeutics: A Contrarian Opportunity in Gene Editing Amid Russell Reconstitution - AInvest

Jun 30, 2025
pulisher
Jun 30, 2025

Top 10 CRISPR Stocks to Buy Now - Insider Monkey

Jun 30, 2025
pulisher
Jun 30, 2025

Beam Therapeutics Inc.(NasdaqGS: BEAM) dropped from Russell 3000 Value Index - MarketScreener

Jun 30, 2025
pulisher
Jun 27, 2025

3 Promising Genomics Stocks to Keep an Eye On in 2025 - The Globe and Mail

Jun 27, 2025
pulisher
Jun 24, 2025

BEAM-101 shows sustained benefits as treatment for sickle cell - Sickle Cell Disease News

Jun 24, 2025
pulisher
Jun 20, 2025

Beam Therapeutics: Progress Of BEAM-101 Presses Forward With H2 2025 Data Releases - Seeking Alpha

Jun 20, 2025
pulisher
Jun 19, 2025

Can Casgevy Deliver a Turnaround for CRISPR Therapeutics? - Yahoo Finance

Jun 19, 2025
pulisher
Jun 18, 2025

Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst - Benzinga

Jun 18, 2025
pulisher
Jun 18, 2025

Gene-Editing Stocks Gain on LLY-VERV Deal Announcement - Yahoo Finance

Jun 18, 2025
pulisher
Jun 17, 2025

Editas Medicine Is Great. Here's Why You Shouldn't Buy It. - The Motley Fool

Jun 17, 2025
pulisher
Jun 17, 2025

BEAM Therapeutics’ SWOT analysis: base editing pioneer’s stock faces pivotal year - Investing.com

Jun 17, 2025
pulisher
Jun 16, 2025

H.C. Wainwright reiterates buy rating on Beam Therapeutics stock By Investing.com - Investing.com Nigeria

Jun 16, 2025
pulisher
Jun 16, 2025

H.C. Wainwright reiterates buy rating on Beam Therapeutics stock - Investing.com

Jun 16, 2025
pulisher
Jun 14, 2025

Cathie Wood’s ARK ETFs adjust holdings, buying GitLab and Beam Therapeutics stock - Investing.com Nigeria

Jun 14, 2025
pulisher
Jun 13, 2025

Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clini - GuruFocus

Jun 13, 2025
pulisher
Jun 13, 2025

Beam Therapeutics Announces New Data from BEACON Phase 1/2 - GlobeNewswire

Jun 13, 2025
pulisher
Jun 13, 2025

Beam Therapeutics (BEAM) Reports Strong Results for Sickle Cell Therapy - GuruFocus

Jun 13, 2025
pulisher
Jun 13, 2025

Beam reports positive results from sickle cell disease treatment - Seeking Alpha

Jun 13, 2025
pulisher
Jun 13, 2025

Beam Therapeutics reports positive data from sickle cell therapy trial - Investing.com

Jun 13, 2025
pulisher
Jun 13, 2025

Beam Therapeutics Reports Positive Update From Sickle Cell Disease Trial - MarketScreener

Jun 13, 2025
pulisher
Jun 13, 2025

Beam Therapeutics reports positive data from sickle cell therapy trial By Investing.com - Investing.com Nigeria

Jun 13, 2025
pulisher
Jun 13, 2025

Beam Therapeutics (BEAM) Releases Promising Data from BEACON Trial | BEAM Stock News - GuruFocus

Jun 13, 2025

빔 테라퓨틱스 (BEAM) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$21.69
price down icon 0.87%
$35.65
price up icon 0.17%
$102.78
price up icon 0.22%
$26.34
price up icon 0.53%
$108.91
price down icon 1.01%
biotechnology ONC
$291.93
price down icon 0.89%
자본화:     |  볼륨(24시간):